Literature DB >> 18619081

Venous thromboembolism during pregnancy.

Lee T Dresang1, Pat Fontaine, Larry Leeman, Valerie J King.   

Abstract

Venous thromboembolism is the leading cause of maternal death in the United States. Pregnancy is a risk factor for deep venous thrombosis, and risk is further increased with a personal or family history of thrombosis or thrombophilia. Screening for thrombophilia is not recommended for the general population; however, testing for inherited or acquired thrombophilic conditions is recommended when personal or family history suggests increased risk. Factor V Leiden and prothrombin G20210A mutation are the most common inherited thrombophilias, and antiphospholipid antibody syndrome is the most important acquired defect. Clinical symptoms of deep venous thrombosis may be subtle and difficult to distinguish from gestational edema. Venous compression (Doppler) ultrasonography is the diagnostic test of choice. Pulmonary embolism typically presents postpartum with dyspnea and tachypnea. Multidetector-row (spiral) computed tomography is the test of choice for pulmonary embolism. Warfarin is contraindicated during pregnancy, but is safe to use postpartum and is compatible with breastfeeding. Low-molecular-weight heparin has largely replaced unfractionated heparin for prophylaxis and treatment in pregnancy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18619081

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  6 in total

1.  Thromboembolism and Thrombosis during Pregnancy and After Delivery between 2009 and 2012 in Al-Zahra Educational Center.

Authors:  Zahra Fardiazar; Khadijeh Hajizadeh; Soudabeh Dinparvar; Fariba Esmaili
Journal:  J Caring Sci       Date:  2014-09-01

Review 2.  Prevention of venous thromboembolism in pregnancy: a review of guidelines, 2000-2011.

Authors:  Ekwutosi M Okoroh; Ijeoma C Azonobi; Scott D Grosse; Althea M Grant; Hani K Atrash; Andra H James
Journal:  J Womens Health (Larchmt)       Date:  2012-05-03       Impact factor: 2.681

3.  Identification of Genetic Interaction with Risk Factors Using a Time-To-Event Model.

Authors:  Mariza de Andrade; Sebastian M Armasu; Bryan M McCauley; Tanya M Petterson; John A Heit
Journal:  Int J Environ Res Public Health       Date:  2017-10-15       Impact factor: 3.390

4.  Sickle cell trait: is there an increased VTE risk in pregnancy and the postpartum?

Authors:  Sofya Pintova; Hillel W Cohen; Henny H Billett
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

5.  Thromboembolic events in pregnant and puerperal women after COVID-19 lockdowns: A retrospective cohort study.

Authors:  Dana Gabrieli; Adva Cahen-Peretz; Tzvika Shimonovitz; Keren Marks-Garber; Hagai Amsalem; Yosef Kalish; Yuval Lavy; Asnat Walfisch
Journal:  Int J Gynaecol Obstet       Date:  2021-07-29       Impact factor: 4.447

6.  Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population.

Authors:  Amy Law; Dominic Pilon; Richard Lynen; François Laliberté; Laurence Gozalo; Patrick Lefebvre; Mei Sheng Duh
Journal:  Reprod Health       Date:  2016-08-22       Impact factor: 3.223

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.